TITLE

Oral-lyn, the Oral Insulin Spray

PUB. DATE
February 2010
SOURCE
Diabetes Health;Feb/Mar2010, Vol. 19 Issue 1, p24
SOURCE TYPE
Periodical
DOC. TYPE
Product Review
ABSTRACT
The article evaluates the Generex Oral-lynâ„¢ insulin spray from Generex Biotechnology Corp.
ACCESSION #
48081504

 

Related Articles

  • Spray On, Insulin Users, Spray On.  // Diabetes Health;Feb/Mar2007, Vol. 16 Issue 1, p29 

    The article announces that Oral-lyn, an insulin spray developed by Generex Biotechnology Corp., has received the 2006 Technology Award for Innovation in the field of diabetic therapies from Frost and Sullivan Co.

  • GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.  // Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p7 

    The article announces that Generex Biotechnology Corp. has received patents in Canada and Argentina. The Canadian Intellectual Property Office has granted Generex a patent that contains process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration,...

  • GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1 

    The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray...

  • GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE.  // Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1 

    The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform....

  • San Antonio Breast Cancer Symposium.  // BioWorld Today;12/9/2011, Vol. 22 Issue 237, p5 

    The article deals with the interim data presented by Generex Biotechnology Corp. at the 2011 San Antonio Breast Cancer Symposium from its continuing Phase II study of the li-Key hybrid-based HER2/neu peptide vaccine in HER2-expressing breast cancer patients.

  • AACR 2012.  // BioWorld Today;4/4/2012, Vol. 23 Issue 65, p7 

    The article reports on Phase II data on AE37, a drug from Generex Biotechnology Corp. designed to increase immune response to human epidermal growth factor receptor 2 (HER2)-expressing cancer cells.

  • Financings Roundup.  // BioWorld Today;2/2/2012, Vol. 23 Issue 13, p4 

    The article reports on the securities purchase agreement of Generex Biotechnology Corp. and on the Series A financing raised by Targovax AS from a Norwegian consortium.

  • Clinic Roundup.  // BioWorld Today;9/19/2011, Vol. 22 Issue 181, p3 

    This section offers news briefs on the biotechnology industry as of September 19, 2011, including a trial of Generex Oral-lyn, a buccal spray insulin, by Generex Biotechnology Corp. and a Phase II/III trial of a vaccine for Japanese encephalitis completed by Intercell AG and Biological E. Ltd.

  • CLINIC ROUNDUP.  // BioWorld Today;5/11/2010, Vol. 21 Issue 90, p2 

    This section offers news briefs on clinical trials including the completion by Generex Biotechnology Corp. of enrollment of patients in its Phase III trial of Generex Oral-lyn and the encouraging pharmacokinetic results obtained by QRxPharma Inc. from its trial of a controlled-release dual-opioid.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics